Molecular Partners and Orano Med Dose First Patients in Phase 1/2a Trial of DLL3-Targeting Radio-DARPin MP0712 — Molecular Partners AG

Event summary

First patients dosed in the Phase 1/2a trial of DLL3-targeting Radio-DARPin MP0712, a collaboration between Molecular Partners and Orano Med.
Five US sites are actively recruiting participants for the study (ClinicalTrials.gov: NCT07278479).
Initial data anticipated within months; comprehensive efficacy results expected in 2027.
MP0712 leverages DLL3 targeting and 212Pb payload, aiming to treat small cell lung cancer (SCLC) and other neuroendocrine tumors.

The big picture

The initiation of this trial underscores the growing interest in targeted alpha therapies (TAT) for oncology, particularly in addressing aggressive cancers like SCLC. Molecular Partners’ Radio-DARPin platform aims to overcome historical limitations of radioligand therapy, positioning it as a key player in the evolving landscape of precision medicine.

What we're watching

Clinical Progress: The pace at which initial data from the Phase 1/2a trial will validate MP0712’s safety and efficacy profile.
Strategic Collaboration: How Molecular Partners and Orano Med’s partnership will expand beyond MP0712 into other Radio-DARPin candidates.
Market Differentiation: Whether the matched-pair approach of diagnostic imaging and therapeutic dosing will enhance MP0712’s competitive edge in radiopharmaceutical therapy.